Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Intracranial aneurysm (IA) is a highly significant comorbid condition of autosomal dominant polycystic kidney disease (ADPKD). To date, no study in Japan has investigated ADPKD-associated IA using genetic analysis. While the prevalence of IA in the general population is reported to be 2–4%, it is markedly higher in ADPKD patients, ranging from 9% to 23%, leading to an increased risk of subarachnoid hemorrhage (SAH). The present study aims to elucidate the prevalence and clinical features of IA and SAH in ADPKD, and to identify associated risk factors, including genetic determinants.
Among 370 ADPKD patients at our institution who provided informed consent and underwent genetic analysis, 70 patients with intracranial aneurysm (IA) or subarachnoid hemorrhage (SAH) were retrospectively identified, and risk factors for IA/SAH were analyzed.
The median age at diagnosis of IA/SAH was 48 years (range, 21–77), with 40% male (n=28) and 60% female (n=42). A family history of IA was observed in 28.6% (n=20), and rupture occurred in 11.4% (n=8). The median aneurysm size was 2.5 mm (range, 1.0–8.0 mm). The distribution of genetic variants among patients with IA/SAH was as follows: PKD1-truncated, 42.6% (n=29); PKD1-non-truncated, 29.7% (n=20); PKD2-truncated, 21.8% (n=14); and PKD2-non-truncated, 6.3% (n=5). These proportions were not significantly different compared with those in the overall ADPKD cohort at our institution. In patients with PKD2-non-truncated variants, however, the likelihood of having a family history of IA was significantly higher (p=0.0213).
Our analysis suggests that there is no difference in aneurysm risk based on ADPKD genotype. This finding indicates that screening for IA and raising awareness of preventive measures are also necessary for patients with PKD2, in whom renal function is relatively preserved. Furthermore, our analysis confirmed that avoiding smoking and achieving early smoking cessation are critical for the prevention of IA/SAH, and that strict blood pressure control is of paramount importance.
